Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
32 hedge funds and large institutions have $6.12M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 5 closing their positions.
3% less funds holding
Funds holding: 33 → 32 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
28% less capital invested
Capital invested by funds: $8.5M → $6.12M (-$2.38M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14.7K |
| 2 |
Renaissance Technologies
New York
|
+$12.6K |
| 3 |
VF
Virtu Financial
New York
|
+$4.88K |
| 4 |
Millennium Management
New York
|
+$599 |
| 5 |
BlackRock
New York
|
+$474 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$139K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$11K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9K |
| 4 |
E
Ergoteles
New York
|
-$8.48K |
| 5 |
Man Group
London,
United Kingdom
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $820 | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $36 | – | – | – |
|
|
NECFA
28
New England Capital Financial Advisors
Meriden,
Connecticut
| $30 | +$17 | +3 | New |
|
29
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $4 | – | – | – |
|
|
AG
30
Artal Group
Luxembourg
| – | -$139K | -21,231 | Closed |
|
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -1,400 | Closed |
|
|
TSS
32
Two Sigma Securities
New York
| – | -$8K | -1,272 | Closed |
|
|
33
Man Group
London,
United Kingdom
| – | -$8K | -1,172 | Closed |
|
34
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$5K | -781 | Closed |
|
35
Simplex Trading
Chicago,
Illinois
| – | -$6 | -1 | -0.7% |
|
SGTX Hedge Fund Activity: Q4 2022 in Review
32 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q4 2022, worth a combined $6.12M — down 28% from $8.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SGTX and 4 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $14.7K. The largest seller was Artal Group, exiting entirely with an estimated $139K sold.
- 32 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q4 2022, down from 33 in Q3 2022.
- Funds reported $6.12M of Sigilon Therapeutics, Inc. Common Stock stock for Q4 2022, down 28% quarter-over-quarter.
- 4 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of -1 holder.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q4 2022 was Citadel Advisors, an estimated $14.7K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q4 2022 was Artal Group, an estimated $139K sold.
Based on aggregated 13F filings for Q4 2022.